<DOC>
	<DOCNO>NCT02150824</DOCNO>
	<brief_summary>Assess safety tolerability daily oral dos BI 187004 patient type 2 diabetes mellitus without oral antidiabetic treatment patient stable metformin background treatment 28 day . Assess effect fast plasma glucose 28 day treatment investigate pharmacokinetics pharmacodynamics BI 187004 .</brief_summary>
	<brief_title>Safety Tolerability , Efficacy , Pharmacokinetic Pharmacodynamic Study Three Doses BI 187004 Over 28 Days Patients With Type 2 Diabetes Mellitus With Without Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male postmenopausal hysterectomised female patient diagnosis Type 2 Diabetes Mellitus ( T2DM ) inform consent 2 . To eligible Arm 1 1 . Oral antidiabetic monotherapy last 12 week prior Informed Consent AND Glycosylated haemoglobin ( HbA1c ) &gt; = 6.5 % &lt; = 8.5 % Visit 1a 2 . Therapynaïve patient antidiabetic treatment within 4 week prior Informed Consent AND HbA1c &gt; = 7.0 % &lt; = 9.5 % Visit 1a . 3 . To eligible Arm 2 : a. Antidiabetic treatment metformin unchanged daily dose 12 week prior Informed Consent AND patient´s willingness keep therapy stable course trial AND HbA1c &gt; = 7.0 % &lt; = 9.5 % Visit 1a 4 . Age &gt; =18 &lt; =80 year female hysterectomised male patient Visit 1a 5 . Age &gt; =55 &lt; =80 year female postmenopausal ( define absence menses least 2 year ) patient Visit 1a 6 . Body mass index ( BMI ) &gt; = 28 &lt; = 40 kg/m2 Visit 1a 7 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Treatment nonoral antidiabetic therapy one oral antidiabetic medication within 12 week prior visit 1a . 2 . Fasted plasma glucose &gt; 240 mg/dl ( &gt; 13.3 mmol/l ) two consecutive day screen ( Visit 1a ) confirm fasted laboratory blood glucose test first administration trial drug 3 . Any laboratory value 3 time upper limit normal ( ULN ) screening ( visit 1a ) laboratory value outside reference range clinically relevant investigator judgment 4 . Any know clinically relevant concomitant diseases chronic disease type 2 diabetes , hyperlipidaemia medically treat hypertension 5 . Medical history cancer treatment cancer last five year prior Visit 1a . 6 . History Cushing syndrome , Addison´s disease , congenital adrenal hyperplasia polycystic ovary syndrome 7 . Treatment systemic , inhalatory ophthalmologic steroid within 12 week prior first administration trial drug . 8 . Treatment compliance runin period outside per protocol range define range , 80 % 120 % treatment compliance . 9 . Use concomitant medication within 5 halflives first administration trial drug except allow comedication . 10 . Surgery trauma significant blood loss ( 500 ml ) within last 3 month prior inform consent blood donation ( 100 ml ) within four week prior first administration study medication plan trial 11 . Any medical condition would interfere trial participation base investigator´s judgement ongoing clinical condition would jeopardize patient´s site personnel´s safety study compliance base investigator judgement . Smoking habit interfere hospitalization . Patients willing abstain alcoholic beverage inpatient visit 12 . Male patient willing use adequate contraception ( sexual abstinence , condom use plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug three month last intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>